Climb Bio rose 405.4% from $1.84 to $9.30, ahead of the S&P 500's +10.2%. Its worst day was Oct 26 (−13.5%), and its low came Nov 21 at $1.70.
Story events cover the past 12 months · Times ET
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Climb Bio closed at its lowest level of the year, 7.6% below where the year started.
−1.7% · S&P 500 +1.0%
Climb Bio shares rose 30.4%, while the S&P 500 fell 1.1%.
+30.4%, the year's best day · S&P 500 −1.1%
Climb Bio shares rose 17.0%, while the S&P 500 rose 1.9%.
+17.0% · S&P 500 +1.9%
EPS of $-0.26 missed the $-0.20 estimate on $0.00 revenue.
+1.5% · S&P 500 −0.6%
EPS of $-0.20 beat the $-0.30 estimate on $0.00 revenue.
−2.5% · S&P 500 −0.3%
EPS of $-0.18 beat the $-0.22 estimate on $0.00 revenue.
+12.3% · S&P 500 −0.2%
Climb Bio closed at its highest level of the year, 869.6% above where the year started.
+8.8% · S&P 500 +0.3%
EPS of $-0.18 beat the $-0.20 estimate on $0.00 revenue.
−4.9% · S&P 500 −4.4%
Where it ended: a close of $9.30 on Nov 18, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-0.19).
Nothing in the past 12 months.
All CLYM dividend history